‘Breakthrough’ Leukemia Drug Also Portends ‘Quantum Leap’ In Cost – Coeur d’Alene Press
|
'Breakthrough' Leukemia Drug Also Portends 'Quantum Leap' In Cost
Coeur d’Alene Press The treatment, CTL019, belongs to a new class of medications called CAR T-cell therapies, which involve harvesting patients' immune cells and genetically altering them to kill cancer. It's been tested in patients whose leukemia has relapsed in spite of … |
